<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001363'>Craniosynostosis</z:hpo> syndromes are <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> human skeletal diseases that result from various mutations in fibroblast growth factor receptor genes (Fgfrs) </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert syndrome</z:e> (AS) is one of the most severe <z:hpo ids='HP_0001363'>craniosynostosis</z:hpo> syndromes and is associated with severe <z:hpo ids='HP_0001159'>syndactyly</z:hpo> of the hands and feet and with central <z:mp ids='MP_0008912'>nervous</z:mp> system malformations </plain></SENT>
<SENT sid="2" pm="."><plain>AS is caused by specific missense mutations in one of two adjacent amino acid residues (S252W or P253R) in the highly conserved region linking Ig-like domains II and III of FGFR2 </plain></SENT>
<SENT sid="3" pm="."><plain>Here we demonstrate that these mutations break one of the cardinal rules governing ligand specificity of FGFR2 </plain></SENT>
<SENT sid="4" pm="."><plain>We show that the S252W mutation allows the mesenchymal splice form of FGFR2 (FGFR2c) to bind and to be activated by the mesenchymally expressed ligands FGF7 or FGF10 and the epithelial splice form of FGFR2 (FGFR2b) to be activated by FGF2, FGF6, and FGF9 </plain></SENT>
<SENT sid="5" pm="."><plain>These data demonstrate loss of ligand specificity of FGFR2 with retained ligand dependence for receptor activation </plain></SENT>
<SENT sid="6" pm="."><plain>These data suggest that the severe phenotypes of AS likely result from ectopic ligand-dependent activation of FGFR2 </plain></SENT>
</text></document>